MedAdvisor (ASX:MDR) - CEO, Robert Read
CEO, Robert Read
Source: Startup Daily
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • MedAdvisor (MDR) has adjusted the price for its capital raise
  • Investors will now be able to grab the health stock’s shares at 38 cents, which is 7 cents cheaper than the initial price
  • The company is aiming to raise $45 million to purchase U.S. based Adheris Health, accelerate its MedAdvisor’s United States’ presence
  • Company shares last traded for 40 cents on October 30

MedAdvisor (MDR) has adjusted the price for its capital raise ahead of its acquisition of U.S.-based Adheris Health.

The company has announced it will change the share price of its capital raise to 38 cents from the previously announced 45 cents-per-share.

This week, MedAdvisor has seen overwhelmingly support from investors since announcing it entered a binding agreement with Syneos Health to purchase Adheris for US$34.5 million (approximately A$47 million).

“Whilst there was strong support at a price premium on MedAdvisor’s last close to 45 cents, including the company’s largest shareholder HMS, it became clear through the engagement process this week that there was stronger support at a 5 per cent discount to the company’s last close of 40 cents,” the company explained.

Under the capital raise, the company is aiming to raise $45 million, with a minimum target of $35 million.

The purchase will accelerate MedAdvisor’s U.S. presence by using Adheris’ existing pharmacy integrations, reducing the need for MedAdvisor to partner with U.S. pharmacies.

MedAdvisor’s and Adheris technology will integrate to create programs that can positively influence patient behaviour from point of initial prescribing to the pharmacy and when at home.

Company shares last traded for 40 cents on October 30.

MDR by the numbers
More From The Market Online
advanced mri or ct scan medical diagnosis machine at hospital lab

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Imricor Medical Systems Ltd intends to use the capital raising's funds to support a three-pronged growth…
Abstract visualization of a brain hemorrhage from an MRI perspective, with vivid colors marking the hemorrhagic areas against the brain's grayscale anatomy.

Trial for Alterity’s neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results…
The Market Online Video

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Recce Pharmaceuticals Ltd has been funded to the tune of US$2M by the US Department of…
AI gen cancer cell

Immutep reports strong response rate from immunotherapies treating carcinomas

Immutep Ltd has reported a slew of positive results from a trial to assess a combination…